Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

Part of paid clinical trials in Chicago, Illinois.

Sponsor
EIP Pharma Inc
Study ID
NCT07033481
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

Eligibility Criteria

Sex
ALL
Age
40 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Neflamapimod — DRUG
    Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40 mg capsules
  • Placebo — DRUG
    Placebo is a capsule that looks just like neflamapimod but without the active ingredients

Study Details

The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.

Key Dates

Start date
Oct 2, 2025
Status verified
Apr 2026
Primary completion
Sep 30, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Neflamapimod
  • Placebo Comparator: Placebo

Primary Outcome Measure

Incidence of Adverse Events and Serious Adverse Events. [ Time Frame: Baseline to Week 36 ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Northwestern Memorial HospitalChicagoIllinois60611-
Mayo ClinicRochesterMinnesota55905-
Columbia UniversityNew YorkNew York10032-
The Ohio State UniversityColumbusOhio43221-
Hospital of the University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Chicago, IL

By research site
Northwestern Memorial Hospital· Chicago, ILMayo Clinic· Rochester, MNColumbia University· New York, NYThe Ohio State University· Columbus, OHHospital of the University of Pennsylvania· Philadelphia, PA

Related Studies